-

Click Therapeutics to Present at the Jefferies Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief Financial Officer, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 4:30 p.m. ET.

Company management will also participate in one-on-one meetings during the conference, which will be held June 8-10, 2022 in New York City.

About Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program has recently entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of Major Depressive Disorder (MDD) in up to 540 adults. Click is progressing a broad pipeline of Digital Therapeutics™ across a variety of high-burden therapeutic areas, including MDD, Schizophrenia, Migraine, Chronic Pain, Atopic Dermatitis, Acute Coronary Syndrome (ACS), Obesity and more. For more information on Click, visit ClickTherapeutics.com.

Contacts

Company Contact
Daniel Busby
VP, Investor Relations & Strategic Finance
dbusby@clicktherapeutics.com

Click Therapeutics, Inc.


Release Summary
Click today announced that it will present at the Jefferies Healthcare Conference on June 9, 2022.
Release Versions

Contacts

Company Contact
Daniel Busby
VP, Investor Relations & Strategic Finance
dbusby@clicktherapeutics.com

Social Media Profiles
More News From Click Therapeutics, Inc.

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First PDT for the Preventive Treatment of Episodic Migraine in the U.S....

Click Therapeutics Underscores Its Commitment to Innovation and Leadership in Software as Prescription Medical Treatments with Launch of New Brand Identity

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Underscores Its Commitment to Innovation and Leadership in Software as Prescription Medical Treatments with New Brand Identity...

Click Therapeutics Launches Software-Enhanced Drug™ Therapies as Part of New Click SE™ Offering

NEW YORK--(BUSINESS WIRE)--Click Therapeutics Launches Software-Enhanced Drug™ Therapies as part of new Click SE™ Offering....
Back to Newsroom